Amgen Inc. $AMGN Shares Acquired by Quadrant Capital Group LLC

Quadrant Capital Group LLC increased its position in shares of Amgen Inc. (NASDAQ:AMGN) by 13.0% in the 4th quarter, Holdings Channel reports. The firm owned 16,751 shares of the medical research company’s stock after purchasing an additional 1,927 shares during the period. Quadrant Capital Group LLC’s holdings in Amgen were worth $5,483,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in AMGN. Norges Bank purchased a new stake in shares of Amgen during the fourth quarter worth approximately $2,164,162,000. Capital World Investors increased its position in shares of Amgen by 22.9% during the fourth quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock worth $7,560,249,000 after purchasing an additional 4,302,237 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Amgen by 7.8% during the fourth quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock worth $4,665,822,000 after purchasing an additional 1,035,779 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Amgen by 1.8% during the fourth quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock worth $17,949,296,000 after purchasing an additional 961,975 shares in the last quarter. Finally, National Bank of Canada FI increased its position in shares of Amgen by 237.7% during the third quarter. National Bank of Canada FI now owns 1,226,372 shares of the medical research company’s stock worth $346,076,000 after purchasing an additional 863,216 shares in the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the company’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the sale, the senior vice president directly owned 7,009 shares in the company, valued at $2,269,023.57. This represents a 15.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.85% of the stock is currently owned by insiders.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen said its phase 3 ABP 938 eye-disease study is advancing, with the drug aimed at challenging Regeneron’s Eylea HD in a major retina market. That keeps Amgen’s pipeline in focus as a potential future growth driver. Article Title
• Positive Sentiment: Amgen also highlighted its MARITIME-SWITCH phase 3 obesity trial, which is designed to capture GLP-1 switchers. Any success in obesity treatment could open another large market and improve long-term revenue expectations. Article Title
• Positive Sentiment: Some coverage pointed to Amgen as a value stock with supportive new data from the VESALIUS-CV cardiovascular study for Repatha, reinforcing confidence in the company’s broader portfolio. Article Title
• Neutral Sentiment: Amgen and outside analysts published bullish commentary on the stock’s valuation and earnings profile, but these were mostly opinion pieces rather than new business developments. Article Title
• Negative Sentiment: Investor sentiment is being pressured by reports that Amgen’s Tavneos faces a proposed FDA withdrawal, with the company seeking a hearing and commissioning an independent review to defend the drug’s data. Regulatory uncertainty around a $500 million product is a meaningful risk for the stock. Article Title
• Negative Sentiment: Reuters also reported that Amgen hired a research firm to reassess Tavneos data after FDA concerns, underscoring the regulatory overhang and near-term uncertainty for the drug. Article Title

Analyst Ratings Changes

Several analysts recently commented on AMGN shares. Piper Sandler reiterated an “overweight” rating on shares of Amgen in a research report on Friday. Jefferies Financial Group started coverage on Amgen in a research report on Tuesday, March 10th. They set a “hold” rating and a $350.00 price target for the company. Rothschild & Co Redburn boosted their price target on Amgen from $180.00 to $200.00 and gave the stock a “sell” rating in a research report on Wednesday, February 18th. Barclays started coverage on Amgen in a research report on Friday, February 20th. They set an “equal weight” rating and a $350.00 price target for the company. Finally, Cantor Fitzgerald reiterated a “neutral” rating and set a $350.00 price target on shares of Amgen in a research report on Wednesday, April 8th. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $354.12.

Amgen Stock Up 0.3%

Shares of NASDAQ:AMGN opened at $355.20 on Friday. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65. The business has a fifty day moving average of $340.97 and a two-hundred day moving average of $345.72. The stock has a market cap of $191.70 billion, a P/E ratio of 24.72, a PEG ratio of 3.55 and a beta of 0.42. Amgen Inc. has a 52-week low of $267.83 and a 52-week high of $391.29.

Amgen (NASDAQ:AMGN) last issued its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.77 by $0.38. The company had revenue of $8.62 billion during the quarter, compared to analysts’ expectations of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The firm’s quarterly revenue was up 5.8% on a year-over-year basis. During the same period in the prior year, the business earned $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, research analysts expect that Amgen Inc. will post 22.38 earnings per share for the current year.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.